Last kr137.00 SEK
Change Today +0.75 / 0.55%
Volume 119.1K
ORX On Other Exchanges
Symbol
Exchange
Stockholm
Berlin
OTC US
OTC US
As of 11:29 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

orexo ab (ORX) Snapshot

Open
kr137.50
Previous Close
kr136.25
Day High
kr139.25
Day Low
kr135.75
52 Week High
03/5/14 - kr170.50
52 Week Low
05/22/14 - kr90.75
Market Cap
4.7B
Average Volume 10 Days
96.6K
EPS TTM
kr-1.81
Shares Outstanding
34.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OREXO AB (ORX)

Related News

No related news articles were found.

orexo ab (ORX) Related Businessweek News

No Related Businessweek News Found

orexo ab (ORX) Details

Orexo AB (publ)., a specialty pharmaceutical company, engages in the development and commercialization of drugs based on patented drug delivery technologies primarily in Sweden and the United States. The company’s product portfolio comprises products on the market, proprietary development programs, and collaboration projects. Its products on the market include Zubsolv sublingual tablets for maintenance treatment of opioid dependence; Abstral for the treatment of breakthrough pain in cancer patients; Edluar, an active substance zolpidem and for the treatment of short-term insomnia; Diabact UBT, which is used to diagnose the presence of Helicobacter pylori, a bacterium that causes gastric ulcers; and Heliprobe System, which is a doctor’s office test to detect the presence of the gastric ulcer bacterium, Helicobacter pylori. The company’s development programs comprise OX51, a sublingual formulation containing alfentanil, which has completed phase II study for the prevention of acute intense pain associated with care-related diagnostic or therapeutic procedures. Its collaboration projects consist of OX-MPI for the treatment of pain and inflammation through collaboration with Boehringer Ingelheim; OX-NLA for the treatment of allergic and non-allergic rhinitis through a partnership with Meda AB; and OX-CLI for the respiratory tract diseases through collaboration with AstraZeneca. Orexo AB (publ). was founded in 1995 and is headquartered in Uppsala, Sweden.

90 Employees
Last Reported Date: 01/29/15
Founded in 1995

orexo ab (ORX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

orexo ab (ORX) Key Developments

Orexo AB (publ) Initiates Launch of a New Higher ZUBSOLV Tablet Strength

­ Orexo AB (publ) announced that it has initiated the launch of a new higher ZUBSOLV tablet strength (8.6 mg/2.1 mg buprenorphine/naloxone CIII sublingual tablets). In December two new dosage strengths of ZUBSOLV were approved by the U.S. Food and Drug A dministration (FDA). Orexo is now prepared to begin distribution and commence the launch of the 8.6 mg dosage, after having received final clearance of the REMS material. The new 8.6 mg dosage complements the existing dosage range of 5.7 mg/1.4 mg and 1.4 mg/0.36 mg tablets enabling more patients to receive their optimal dose in one tablet. The new ZUBSOLV dosage strength is based on the same advanced, proprietary sublingual tablet formulation used for the already launched ZUBSOLV tablets, providing higher bioavailability, fast dissolve time, small tablet size, and menthol flavor. The new dosage is expected to be available for patients in the first half of March.

Orexo AB Reports Consolidated and Parent Company Earnings Results for the Fourth Quarter and Year Ended December 2014

Orexo AB reported consolidated and parent company earnings results for the fourth quarter and year ended December 2014. For the quarter, the company reported consolidated net revenues of SEK 220.5 million against SEK 99.5 million a year ago. Operating earnings were SEK 59.0 million against operating loss of SEK 31.7 million a year ago. Earnings before tax was SEK 52.9 million against loss before tax of SEK 36.3 million a year ago. Net earnings for the period was SEK 51.6 million against net loss for the period of SEK 37.8 million a year ago. Earnings per share, after dilution was SEK 1.46 against loss per share, after dilution of SEK 1.19 a year ago. Cash outflow from operating activities was SEK 7.3 million compared to SEK 115.5 million a year ago. Acquisition of tangible and intangible fixed assets were SEK 7.8 million compared to SEK 61.5 million a year ago. Return on equity was 13% compared to negative return on equity of 22% a year ago. For the year, on consolidated basis, the company reported net revenues of SEK 570.3 million against SEK 429.4 million a year ago. Operating loss was SEK 25.0 million against SEK 139.7 million a year ago. Loss before tax was SEK 52.6 million against SEK 153.4 million a year ago. Net loss for the period was SEK 56.6 million against net loss for the period of SEK 154.9 million a year ago. Loss per share, after dilution was SEK 1.73 against loss per share, after dilution of SEK 5.16 a year ago. Cash outflow from operating activities was SEK 487.3 million compared to SEK 265.8 million a year ago. Acquisition of tangible and intangible fixed assets were SEK 71.7 million compared to SEK 107.5 million a year ago. Negative return on equity was 27% compared to 88% a year ago. Net debt was negative SEK 211.8 million against SEK 135.4 million a year ago. For the quarter, the company reported parent net revenues of SEK 142.8 million against SEK 43.5 million a year ago. Operating earnings were SEK 39.8 million against operating loss of SEK 65.3 million a year ago. Earnings before tax was SEK 34.0 million against loss before tax of SEK 70.0 million a year ago. Net earnings for the period was SEK 33.6 million against net loss for the period of SEK 71.5 million a year ago. For the year, the parent company reported net revenues of SEK 398.5 million against SEK 452.3 million a year ago. Operating loss was SEK 39.5 million against SEK 27.9 million a year ago. Loss before tax was SEK 65.4 million against SEK 44.3 million a year ago. Net loss for the period was SEK 65.9 million against net loss for the period of SEK 45.8 million a year ago.

Orexo AB, 2014 Earnings Call, Jan 29, 2015

Orexo AB, 2014 Earnings Call, Jan 29, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ORX:SS kr137.00 SEK +0.75

ORX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ORX.
View Industry Companies
 

Industry Analysis

ORX

Industry Average

Valuation ORX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 7.6x
Price/Book 9.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OREXO AB, please visit www.orexo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.